This study demonstrated the potential use of the CD4:CD8 ratio as a complementary measure to eGFR and ACR to aid the early identification of PLWH who may be at elevated risk of developing CKD, and could therefore benefit from closer longitudinal monitoring of their renal function. This evidence concerns the gene CD8A and chronic kidney disease.